Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Marker Therapeutics, Inc. | mrkr-20200930xex32d2.htm |
| EX-31.2 - EXHIBIT 31.2 - Marker Therapeutics, Inc. | mrkr-20200930xex31d2.htm |
| EX-31.1 - EXHIBIT 31.1 - Marker Therapeutics, Inc. | mrkr-20200930xex31d1.htm |
| EX-10.2 - EXHIBIT 10.2 - Marker Therapeutics, Inc. | mrkr-20200930xex10d2.htm |
| EX-10.1 - EXHIBIT 10.1 - Marker Therapeutics, Inc. | mrkr-20200930xex10d1.htm |
| 10-Q - FORM 10-Q - Marker Therapeutics, Inc. | mrkr-20200930x10q.htm |
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The undersigned, Peter L. Hoang, the Chief Executive Officer of Marker Therapeutics, Inc. (the “Company”) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Quarterly Report on Form 10-Q for the period ending September 30, 2020, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company.
Date: | November 9, 2020 | |
| | |
| /s/ Peter L. Hoang | |
| Peter L. Hoang | |
| Chief Executive Officer (Principal Executive Officer) | |